Coloplast A/S Class B · OMXCOP:COLO_B
Coloplast A/S Class B — ESG Presentation (January 2011)
24 slides from Coloplast A/S Class B's sustainability presentation, Jan 6, 2011
Slide 1: Corporate Responsibility
Corporate Responsibility Lyon 6 Jan 2011 Coloplast / Oddo Securities 19 August 2010 Leading intimate healthcare
Slide 2: Responsibility will help drive growth
Page 2 Responsibility will help drive growth A key driver for our future growth is to show how product corporate responsibility go hand in hand with good business. When you buy a Coloplast product, you buy a product that is safe to use and minimises any harm to the environment. You buy a product pro
Slide 3: Responsibility will help drive growth
Page 3 Responsibility will help drive growth An example: SpeediCath® Compact and SpeediBag® Compact. This catheter and urine bag are just half the size of standard products. This means that they: Are discrete and easily slips into a pocket Require less production materials Are lighter and more
Slide 4: Did you know that...
Page 4 Did you know that... 38% of managers in Coloplast are women? our employee injury rate has fallen by over 50% over the last 4 years? we have reduced waste levels by 6% per produced unit in a year? we offer phthalate-free alternatives to 80% of our products which contain phthalates? o
Slide 5: Our stakeholders and responsibilities
Page 5 Our stakeholders and responsibilities End users Business partners Making safe and Helping our suppliers and comfortable products for the distributors raise their people who need them. standards. Employees Environment Ensuring the health and Making our products safety of our employees. sustain
Slide 6: Corporate governance
Page 6 Corporate governance Board of Directors independence: Five of seven members independent No-one member of both Executive Management and Board of Directors Audit committee established 2009 Remuneration: Members of the Board: fixed annual fee; no incentive pay Chairman and Deputy Chair
Slide 7: Phasing out phthalates
Page 7 Quality and safety Phasing out phthalates Phthalates are used to soften e.g. catheters and urine bags. Studies beginning to raise concerns as to the safe levels of use of phthalates Since 2008 all new Coloplast products have been produced without phthalates. We are just five products
Slide 8: Other ingredients to watch
Page 8 Quality and safety Other ingredients to watch Apart from phthalates we follow the latest research on potential harmful effects of a number of other product ingredients: PVC: We have committed ourselves to do our best to avoid PVC in new products. We try to make PVC free versions when renewi
Slide 9: Respecting their independence
Page 9 Health care professionals Respecting their independence We follow European and American industry ethical Codes. This means: No corruption and bribery Modest gifts and entertainment Appropriate support for education Appropriate remuneration This year, we trained 22% of white-collar wor
Slide 10: Responsible advocacy
Page 10 Health care professionals Responsible advocacy We work in partnership with many stakeholders to try to influence decisions that affect our industry and rights of end users. Key objectives include: Ban on phthalates in medical devices Raise awareness of and improve the standard of care wi
Slide 11: Reducing injuries
Page 11 Employees Reducing injuries At Coloplast, we are particularly vigilant about injuries at the workplace. We register all injuries and near-misses. Total frequency of injuries has decreased by approximately 54% over the last four years* Already below our targets for both total and producti
Slide 12: Repetitive work
Page 12 Employees Repetitive work Big fall in repetitive work (RW) over last three years: Workplaces with very high RW down from 7% to 3.8% Workplace with high RW down from 20% to 12% In China, for example, we are rotating employees every fourth hour. 19 August 2010 Leading intimate healthcare
Slide 13: Engagement
Page 13 Employees Engagement In recent years, Coloplast has moved production and support functions to China, Hungary and Poland. Employees laid off in Denmark, the US and other countries received additional severance pay and outplacement assistance. Meanwhile, we are above target on all three measur
Slide 14: Diversity of the workforce
Page 14 Employees Diversity of the workforce We believe that diversity is a competitive advantage as it brings different sets of ideas to our innovation process. Coloplast is a female-dominated workplace and women are represented in some of the most influential parts of the company. 19 August 2010 L
Slide 15: Helping them meet our standards
Page 15 Business partners Helping them meet our standards Our CR Standards only makes sense if business partners also follow them. Our formula: Set standards: booklet, detailed requirements matrix Help comply: self-assessment, site visits, action plans Check compliance: 98% of suppliers screen
Slide 16: Helping them meet our standards
Page 16 Business partners Helping them meet our standards Employees: Machine safety, protective gear, chemicals, noise Fire control, housing conditions, canteen, toilets Minimum wage, overtime, sanctions, child labour Environment: Waste handling, hazardous waste, water treatment and discharg
Slide 17: Doing our part
Page 17 The environment Doing our part We want to emit less CO2 and generate less waste. This year we’ve achieved: 3% reduction in CO2 per produced unit 28% reduction in CO2 per EBIT Initiatives to greenhouse gas emissions include: 17% reduction in air travel Heat recovery system in Hungary
Slide 18: Doing our part
Page 18 The environment Doing our part Throwing out raw materials as waste is bad business and bad for the environment. The last year we’ve : Achieved a 6% reduction of waste per produced unit Recycled 12% more waste than previous year Nearly doubled the amount of waste sent to incineration ra
Slide 19: Increasing the access to healthcare
Page 19 Strategic partnerships Increasing the access to healthcare Access to Healthcare is Coloplast’s partnership program for developing countries. The aim is to give people in developing countries better access to intimate healthcare. Coloplast has committed 50 M DKK over ten years. To date we’ve
Slide 20: Increasing the access to healthcare
Page 20 Strategic partnerships Increasing the access to healthcare Wound care, India Ostomy guidelines, China Training of 4,500 nurses in ostomy care Putting ostomy care on the agenda in E-learning and practical training China, involving more than 600 www.iscnep.org hospitals Creating Chinas first n
Slide 21: Organisation of our corporate responsibility work
Page 21 Organisation of our corporate responsibility work In Coloplast, corporate responsibility is a key foundation for the corporate and business area strategies and the day-to-day Agenda. A central Corporate Responsibility unit sets policies and coordinates the work of line and specialist functio
Slide 22: Our standards
Page 22 Our standards Human rights, labour The Coloplast Code of Our Global Reporting ISO 9001 100% rights, environment Conduct outlines our Initiative (GRI) is the ISO 13485 100% standards and anti- business ethics. world’s most used corruption. sustainability reporting ISO 14001 91% Coloplast sign
Slide 23: Learn more
Page 23 Learn more Corporate Responsibility Pocketbook version Investor ratings Report 19 August 2010 Leading intimate healthcare
Slide 24: Contact
Page 24 Contact Corporate Responsibility Manager Jeppe Kromann Haarsted DKJKMH@coloplast.com +45 4911 1621 http://www.coloplast.com/about/responsibility/pages/responsibility.aspx 19 August 2010 Leading intimate healthcare